Reported frequencies of genetic alterations in major hallmarks of cHL pathobiology
| Pathway/gene . | Genomic alteration . | Frequency, % . | Reference . |
|---|---|---|---|
| NF-κB | |||
| NFKBIA | SNV | 25-40 | 68,69 |
| NFKBIE | SNV | 17-27 | 70,71 |
| REL | CNV gain/amp | 28-70 | 63,65,66 |
| MAP3K14 | CNV gain/amp | 25 | 66 |
| TNFAIP3 | SNV | 40-45 | 72,73,140 |
| CNV loss | 21-60 | 65,66,74 | |
| BCL3 | CNV gain | 15-70 | 65,-67 |
| SR | 10 | 67 | |
| JAK-STAT | |||
| JAK2 | CNV gain/amp | 35-40 | 66,75,76 |
| SOCS1 | SNV | 41 | 77 |
| PTPN1 | SNV | 20 | 78 |
| STAT6 | SNV | 31-45 | 84,140 |
| Immune escape | |||
| CIITA | SR | 15 | 141 |
| CD274/PDC1LG2 | CNV gain/amp | 38-75 | 76,99 |
| B2M | SNV | 21-70 | 50,140 |
| CD58 | CNV loss | 23 | 142 |
| TNFRSF14 | CNV loss | 13-42 | 66,117 |
| Pathway/gene . | Genomic alteration . | Frequency, % . | Reference . |
|---|---|---|---|
| NF-κB | |||
| NFKBIA | SNV | 25-40 | 68,69 |
| NFKBIE | SNV | 17-27 | 70,71 |
| REL | CNV gain/amp | 28-70 | 63,65,66 |
| MAP3K14 | CNV gain/amp | 25 | 66 |
| TNFAIP3 | SNV | 40-45 | 72,73,140 |
| CNV loss | 21-60 | 65,66,74 | |
| BCL3 | CNV gain | 15-70 | 65,-67 |
| SR | 10 | 67 | |
| JAK-STAT | |||
| JAK2 | CNV gain/amp | 35-40 | 66,75,76 |
| SOCS1 | SNV | 41 | 77 |
| PTPN1 | SNV | 20 | 78 |
| STAT6 | SNV | 31-45 | 84,140 |
| Immune escape | |||
| CIITA | SR | 15 | 141 |
| CD274/PDC1LG2 | CNV gain/amp | 38-75 | 76,99 |
| B2M | SNV | 21-70 | 50,140 |
| CD58 | CNV loss | 23 | 142 |
| TNFRSF14 | CNV loss | 13-42 | 66,117 |
amp, amplification; CNV, copy number variation; SNV, single-nucleotide variants (including small deletions); SR, structural rearrangement.